Plasma Levels of E-cadherin and MMP-13 in Prostate Cancer Patients: Correlation with PSA, Testosterone and Pathological Parameters

Aims and Background Prostate cancer is the most common malignant tumor in men. Serum prostate-specific antigen (PSA), Gleason score and clinical range at the time of diagnosis are important factors to predict prognosis and outcome after therapy but additional accurate and reliable biomarkers are still wanted. So far, few biomarkers of prostate cancer have been successfully implemented and are being used in clinical practice. However, modifications of E-cadherin and MMP-13 expression are likely to be involved in prostate cancer invasion and thus are potential biomarkers for prognosis. Patients and Methods We analyzed the concentrations of E-cadherin and MMP-13 in plasma of patients with prostate cancer at diagnosis and 3 and 6 months after the beginning of treatment and related these measures to free and total PSA and other clinical features. Results The concentration of E-cadherin was lower in patients with prostate cancer compared to the control group, but there was no difference in the concentration of MMP-13 between these two groups. During treatment, however, we found no significant differences between the concentrations of MMP-13 and E-cadherin, but we observed a significant positive correlation between total PSA and E-cadherin plasma concentration at the third month of treatment and between total testosterone and MMP-13 plasma concentration before the start of treatment. Conclusions The results suggest that these parameters could be used both in the diagnosis and prognosis of prostate cancer.

[1]  A. Giglio,et al.  Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients , 2013, Tumor Biology.

[2]  A. Giglio,et al.  Characterization of cell-free circulating DNA in plasma in patients with prostate cancer , 2013, Tumor Biology.

[3]  K. Iczkowski,et al.  Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents , 2012, Medicinal research reviews.

[4]  M. Carini,et al.  The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml , 2012, International Urology and Nephrology.

[5]  A. Scherag,et al.  Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy , 2011, International journal of cancer.

[6]  Oscar R. Miranda,et al.  Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples , 2011, Scandinavian journal of urology and nephrology.

[7]  N. Kyprianou,et al.  Role of androgens and the androgen receptor in epithelial‐mesenchymal transition and invasion of prostate cancer cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  K. Gravdal,et al.  A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer , 2007, Clinical Cancer Research.

[9]  Y. Collan,et al.  Prognostic factors in prostate cancer , 2006, Diagnostic pathology.

[10]  Lynette M. Smith,et al.  Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. , 2005, Urologic oncology.

[11]  Eva M. Schmelz,et al.  Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. , 2005, Neoplasia.

[12]  G. Morgia,et al.  Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer , 2005, Urological Research.